Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Meta Expands AI Training With Employee Activity Tracking Tools 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
SOUTH SAN FRANCISCO, Calif., March 20, 2017 -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced that it intends to offer and sell, subject to market and other conditions, 4,500,000 shares of its common stock in an underwritten public offering. All of the shares of common stock are being offered by Calithera. In connection with this offering, Calithera expects to grant the underwriters a 30-day option to purchase up to 675,000 additional shares of common stock.
Leerink Partners is acting as sole book-running manager for the offering. Wells Fargo Securities is acting as a lead manager and JMP Securities is acting as a co-manager for the offering. The Offering is subject to market conditions, as well as NASDAQ approval, and there can be no assurance as to whether or when the Offering may be completed, or the actual size or terms of the Offering.
A shelf registration statement relating to the offered shares of common stock was filed with the Securities and Exchange Commission (SEC), and was declared effective on November 24, 2015. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website, located at www.sec.gov. Copies of the prospectus related to the offering may be obtained, when available, from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA, 02110, by email at [email protected], or by telephone at (800) 808-7525, ext. 6132.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Calithera
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera is headquartered in South San Francisco, California.
Investor Relations Contact: Jennifer McNealey [email protected] 650-870-1071
